Vogenx Inc. (VOGX)

Profile

https://vogenx.com

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. The company’s current work centers on diseases linked to human metabolism dysfunction, including post-bariatric hypoglycemia and gastroparesis. Its lead product candidate, mizagliflozin, is an orally administered small-molecule drug designed to modulate glucose absorption through SGLT1 inhibition. Vogenx also studies additional metabolic indications such as obesity and related postprandial disorders, reflecting a pipeline aimed at conditions with limited treatment options. Headquartered in Raleigh, North Carolina, Vogenx operates as a drug development business within the healthcare sector, where its role is to advance investigational therapies through clinical testing and toward potential regulatory review.